AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24103561 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement protocol including polysomnography and specific questionnaires
Number of subjects: 0
Study 20528209 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial trauma during embryo transfer trials (ETTs) performed on day 21 of the previous cycle
Number of subjects: 150
Study 20528209 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial trauma during embryo transfer trials (ETTs) performed on day 6 of the controlled ovarian hyperstimulation (COH) cycle
Number of subjects: 150
Study 20528209 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial trauma during embryo transfer trials (ETTs) conducted at least two cycles before COH cycle
Number of subjects: 150
Study 19148113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving parents (e.g., parent education, infant stimulation, home visits, individualized developmental care)
Number of subjects: 2198
Study 19148113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving parents
Number of subjects: 2198
Study 17942775 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruption of fibrin sheaths via angioplasty
Number of subjects: 47
Study 17942775 — intervention group
Group type: COMPARATOR
Intervention: No disruption of fibrin sheaths
Number of subjects: 47
Study 17942775 — intervention group
Group type: EXPERIMENTAL
Intervention: No sheaths present
Number of subjects: 47
Study 17942775 — intervention group
Group type: COMPARATOR
Intervention: Sheaths present and not disrupted
Number of subjects: 47
Study 15547184 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A)
Number of subjects: 237
Study 15547184 — intervention group
Group type: COMPARATOR
Intervention: Locoregional treatment alone (group B)
Number of subjects: 237
Study 15547184 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) among operable patients
Number of subjects: 237
Study 15547184 — intervention group
Group type: COMPARATOR
Intervention: Locoregional treatment alone (group B) among operable patients
Number of subjects: 237
Study 15547184 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) among inoperable patients
Number of subjects: 237
Study 15547184 — intervention group
Group type: COMPARATOR
Intervention: Locoregional treatment alone (group B) among inoperable patients
Number of subjects: 237
Study 11535479 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg IM or 2.5 mg IV)
Number of subjects: 168
Study 11535479 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine (10 mg IM or 10 mg IV)
Number of subjects: 168
Study 11535479 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 168
Study 11535479 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 168
Study 9481998 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin phonophoresis (1% indomethacin cream with ultrasound massage at 1.0 MHz, 0.8 to 1.5 W/cm2 for 15 minutes)
Number of subjects: 20
Study 9481998 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream with ultrasound massage (1.0 MHz, 0.8 to 1.5 W/cm2 for 15 minutes)
Number of subjects: 20
Study 8174987 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg daily for five days
Number of subjects: 8
Study 8174987 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 8
Study 3356083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (group 1)
Number of subjects: 2
Study 3356083 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (group 1)
Number of subjects: 2
Study 3356083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (group 2)
Number of subjects: 2
Study 3356083 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (group 2)
Number of subjects: 2
Study 28737966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal corticosteroid treatment (mometasone)
Number of subjects: 236
Study 28737966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 26694228 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 18
Study 26694228 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength followed by endurance training (ST-END)
Number of subjects: 18
Study 26694228 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance followed by strength training (END-ST)
Number of subjects: 18
Study 25006066 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0.21% S; CON)
Number of subjects: 18
Study 25006066 — intervention group
Group type: EXPERIMENTAL
Intervention: High S diet (0.51% S; HS)
Number of subjects: 18
Study 25006066 — intervention group
Group type: EXPERIMENTAL
Intervention: High S diet + 300 mg of ferric Fe from FAC/kg DM (HS+Fe)
Number of subjects: 18
Study 22791090 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 477
Study 20608635 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail Antirotation (PFNA)
Number of subjects: 136
Study 20608635 — intervention group
Group type: COMPARATOR
Intervention: Gamma Nail 3 (GN-3)
Number of subjects: 136
Study 18337483 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus/sirolimus
Number of subjects: 132
Study 18337483 — intervention group
Group type: COMPARATOR
Intervention: mycophenolate mofetil (MMF)/sirolimus
Number of subjects: 132
Study 16329761 — intervention group
Group type: EXPERIMENTAL
Intervention: high-SFA diet (20 energy %)
Number of subjects: 20
Study 16329761 — intervention group
Group type: EXPERIMENTAL
Intervention: high-USFA diet (24 energy %)
Number of subjects: 20
Study 16329761 — intervention group
Group type: EXPERIMENTAL
Intervention: high-USFA diet
Number of subjects: 20
Study 15549368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise with series (IEs)
Number of subjects: 11
Study 15549368 — intervention group
Group type: COMPARATOR
Intervention: Intermittent exercise without series (IE)
Number of subjects: 11
Study 11095440 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (Humatrope, Eli Lilly & Co.) at a dose of 0.05 IU/kg/week for 1 month, then 0.1 IU/kg/week divided into daily subcutaneous injections (0.75-1.25 IU/day) for 6 months followed by 12 months of open treatment.
Number of subjects: 31
Study 11095440 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 months.
Number of subjects: 31
Study 8820895 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 10
Study 8820895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen/oxygen mixture (hypoxic gas)
Number of subjects: 10
Study 1316041 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-gentamicin
Number of subjects: 170
Study 1316041 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin-doxycycline
Number of subjects: 170
Study 4045047 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis therapy
Number of subjects: 1921
Study 4045047 — intervention group
Group type: COMPARATOR
Intervention: No digitalis therapy (placebo)
Number of subjects: 1921
Study 4045047 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis therapy (adjusted)
Number of subjects: 1921
Study 4045047 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis therapy (multiple logistic regression)
Number of subjects: 1921
Study 3040835 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (50 mg/day for 4 days)
Number of subjects: 2
Study 3040835 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2
Study 31865633 — intervention group
Group type: EXPERIMENTAL
Intervention: U-500R via continuous subcutaneous insulin infusion (CSII)
Number of subjects: 420
Study 31865633 — intervention group
Group type: COMPARATOR
Intervention: U-500R via multiple daily injections (MDI)
Number of subjects: 420
Study 30896356 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration (HypoH)
Number of subjects: 11
Study 30896356 — intervention group
Group type: COMPARATOR
Intervention: Euhydration (EuH)
Number of subjects: 11
Study 28532874 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape (KT)
Number of subjects: 46
Study 28532874 — intervention group
Group type: COMPARATOR
Intervention: Postural correction exercises
Number of subjects: 46
Study 26168982 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m² i.v. on day 1 of 3-week cycle
Number of subjects: 111
Study 26168982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m² i.v. on days 1 and 8 of 3-week cycle
Number of subjects: 111
Study 23248172 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 alone
Number of subjects: 10
Study 23248172 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon alone
Number of subjects: 10
Study 23248172 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 plus glucagon
Number of subjects: 10
Study 23248172 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 21987700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing conservation intervention (3-year duration)
Number of subjects: 392
Study 21987700 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 392
Study 18314098 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational model of spatial visualization capacity
Number of subjects: 0
Study 18314098 — intervention group
Group type: EXPERIMENTAL
Intervention: Parameter-value fitting experiment
Number of subjects: 0
Study 18314098 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication experiment without further fitting
Number of subjects: 0
Study 16848802 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg three times daily (t.i.d.)
Number of subjects: 31
Study 16848802 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily (b.i.d.)
Number of subjects: 31
Study 16848802 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg three times daily (t.i.d.)
Number of subjects: 31
Study 11907418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 8
Study 11907418 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 8
Study 10208556 — intervention group
Group type: EXPERIMENTAL
Intervention: Subordinate level categorizations
Number of subjects: 0
Study 10208556 — intervention group
Group type: EXPERIMENTAL
Intervention: Superordinate level categorizations
Number of subjects: 0
Study 10208556 — intervention group
Group type: COMPARATOR
Intervention: Basic level categorizations
Number of subjects: 0
Study 8573841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 36
Study 8573841 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 36
Study 8573841 — intervention group
Group type: COMPARATOR
Intervention: Full polysomnography
Number of subjects: 36
Study 8573841 — intervention group
Group type: COMPARATOR
Intervention: Overnight home monitoring of nasal airflow and arterial oxygen saturation
Number of subjects: 36
Study 1964580 — intervention group
Group type: EXPERIMENTAL
Intervention: visacor
Number of subjects: 126
Study 1964580 — intervention group
Group type: EXPERIMENTAL
Intervention: doxazosin
Number of subjects: 126
Study 1964580 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapamil
Number of subjects: 126
Study 1964580 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine
Number of subjects: 126
Study 1964580 — intervention group
Group type: EXPERIMENTAL
Intervention: perindoprilat
Number of subjects: 126
Study 1964580 — intervention group
Group type: EXPERIMENTAL
Intervention: dilevalol
Number of subjects: 126
Study 1964580 — intervention group
Group type: EXPERIMENTAL
Intervention: carvedilol
Number of subjects: 126
Study 1964580 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 126
Study 642556 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (ATS)
Number of subjects: 114
Study 642556 — intervention group
Group type: COMPARATOR
Intervention: Bank blood transfusion (control)
Number of subjects: 114
Study 31812337 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for ≤24 hours
Number of subjects: 704
Study 31812337 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics for ≥96 hours
Number of subjects: 704
Study 29203067 — intervention group
Group type: EXPERIMENTAL
Intervention: Target IOP of 6 mmHg
Number of subjects: 571
Study 29203067 — intervention group
Group type: EXPERIMENTAL
Intervention: Target IOP of 15 mmHg
Number of subjects: 571
Study 29203067 — intervention group
Group type: EXPERIMENTAL
Intervention: Target IOP of 24 mmHg
Number of subjects: 571
Study 26854780 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronoid process graft (CPG)
Number of subjects: 10
Study 26854780 — intervention group
Group type: COMPARATOR
Intervention: Costochondral graft (CCG)
Number of subjects: 10
Study 25278424 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline counselling
Number of subjects: 512
Study 25278424 — intervention group
Group type: COMPARATOR
Intervention: Self-help brochure
Number of subjects: 512
Study 22570108 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer and practice team intervention (three monthly calls from trained peer patients and two practice staff visits)
Number of subjects: 280
Study 22570108 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer and practice team intervention
Number of subjects: 280
Study 22570108 — intervention group
Group type: COMPARATOR
Intervention: Usual physician care and brochures about healthy cooking and heart disease (Control)
Number of subjects: 280
Study 21211279 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-catheter epidural block (group D, n = 103)
Number of subjects: 206
Study 21211279 — intervention group
Group type: COMPARATOR
Intervention: Single-catheter epidural block (group S, n = 103)
Number of subjects: 206
Study 21211279 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-catheter epidural block (group D)
Number of subjects: 206
Study 21211279 — intervention group
Group type: COMPARATOR
Intervention: Single-catheter epidural block (group S)
Number of subjects: 206
Study 18946418 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended anticoagulation for 18 months (INR between 2 and 3)
Number of subjects: 374
Study 18946418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 16648017 — intervention group
Group type: EXPERIMENTAL
Intervention: sips and gum chewing (treatment, n = 22)
Number of subjects: 66
Study 16648017 — intervention group
Group type: COMPARATOR
Intervention: sips (control, n = 21)
Number of subjects: 66
Study 16648017 — intervention group
Group type: COMPARATOR
Intervention: sips and accupressure wrist bracelet (placebo, n = 23)
Number of subjects: 66
Study 14713377 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance from teachers
Number of subjects: 31
Study 14713377 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance from parents
Number of subjects: 31
Study 14713377 — intervention group
Group type: COMPARATOR
Intervention: Control group (swapped intervention)
Number of subjects: 31
Study 10229057 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-418 (6 mg)
Number of subjects: 6
Study 10229057 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-418 (12 mg)
Number of subjects: 6
Study 10229057 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-418 (23 mg)
Number of subjects: 6
Study 10229057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8915564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (3.4 ± 1.6 mg)
Number of subjects: 26
Study 8915564 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3.5 ± 2.2 mg/day)
Number of subjects: 26
Study 8915564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1901083 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of immune globulin (IVIG) per kilogram of body weight
Number of subjects: 22
Study 1901083 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (albumin)
Number of subjects: 22
Study 6166982 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (SMC) 2.5 micrograms/h
Number of subjects: 40
Study 6166982 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (control)
Number of subjects: 40
Study 31975558 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 45
Study 31975558 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 45
Study 31975558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30679724 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (exact dosage and duration not specified)
Number of subjects: 82
Study 30679724 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=58)
Number of subjects: 82
Study 28939263 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (stretching exercises)
Number of subjects: 142
Study 28939263 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and ergonomic modification group
Number of subjects: 142
Study 28939263 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 142
Study 28939263 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 142
Study 27053773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus using PPD
Number of subjects: 8
Study 27053773 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (physician guidance)
Number of subjects: 8
Study 23919483 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alcohol (1 ml/kg body weight of 94% alcohol, 0.75 g/kg)
Number of subjects: 26
Study 23919483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22048261 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 44
Study 22048261 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 22048261 — intervention group
Group type: COMPARATOR
Intervention: Passive stretching
Number of subjects: 44
Study 19632666 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert users
Number of subjects: 48
Study 19632666 — intervention group
Group type: COMPARATOR
Intervention: Novice users
Number of subjects: 48
Study 19632666 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fidelity prototypes
Number of subjects: 48
Study 18283207 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT extension for nonpharmacologic treatments
Number of subjects: 0
Study 18283207 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15983524 — intervention group
Group type: EXPERIMENTAL
Intervention: NuSun sunflower oil diet
Number of subjects: 31
Study 15983524 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil diet
Number of subjects: 31
Study 15983524 — intervention group
Group type: COMPARATOR
Intervention: Average American diet
Number of subjects: 31
Study 12608908 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (MNZ)
Number of subjects: 40
Study 12608908 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM)
Number of subjects: 40
Study 12608908 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 40
Study 11157431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 0
Study 11157431 — intervention group
Group type: COMPARATOR
Intervention: Normal IQ patients
Number of subjects: 0
Study 8866563 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg troglitazone daily for 12 weeks
Number of subjects: 42
Study 8866563 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg troglitazone daily for 12 weeks
Number of subjects: 42
Study 8866563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8866563 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg and 400 mg)
Number of subjects: 42
Study 8866563 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 42
Study 1506638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 187
Study 6088713 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy 6000 rads/7 weeks plus CCNU 130 mg/M2 every 6 weeks
Number of subjects: 115
Study 6088713 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy 6000 rads/7 weeks plus CCNU 75 mg/M2 day 1 plus procarbazine 100 mg/m2 days 1‐14 every 6 weeks
Number of subjects: 115
Study 31819122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate solution (40 ml/kg)
Number of subjects: 12
Study 31819122 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose water (20 ml/kg)
Number of subjects: 12
Study 31819122 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% tetrastarch (1000 ml)
Number of subjects: 12
Study 31819122 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% pentastarch (1000 ml)
Number of subjects: 12
Study 29878269 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-ingredient protein-based supplement (30 g whey protein, 2.5 g creatine, 500 IU vitamin D, 400 mg Ca, 1500 mg n-3 polyunsaturated fatty acids) taken 2 times/day for 7 weeks
Number of subjects: 27
Study 29878269 — intervention group
Group type: COMPARATOR
Intervention: Control group (22 g maltodextrin)
Number of subjects: 27
Study 26270469 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleach baths
Number of subjects: 40
Study 26270469 — intervention group
Group type: COMPARATOR
Intervention: Water baths
Number of subjects: 40
Study 24650336 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration combined with counter‐movement jumping (WBV + CMJ)
Number of subjects: 24
Study 24650336 — intervention group
Group type: COMPARATOR
Intervention: Counter‐movement jumping (CMJ)
Number of subjects: 24
Study 21995889 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review therapy
Number of subjects: 202
Study 21995889 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 202
Study 20695770 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC/E2
Number of subjects: 48
Study 20695770 — intervention group
Group type: COMPARATOR
Intervention: DRSP/EE
Number of subjects: 48